|
1
|
Honigsbaum M: Revisiting the 1957 and 1968
influenza pandemics. Lancet. 395:1824–1826. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gilbert MTP, Rambaut A, Wlasiuk G, Spira
TJ, Pitchenik AE and Worobey M: The emergence of HIV/AIDS in the
Americas and beyond. Proc Natl Acad Sci USA. 104:18566–18570.
2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nalbandian A, Sehgal K, Gupta A, Madhavan
MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat
TS, et al: Post-acute COVID-19 syndrome. Nat Med. 27:601–615.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Porritt AE: The discovery and development
of penicillin. Med Press. 225:460–462. 1951.PubMed/NCBI
|
|
5
|
Bryan-Marrugo OL, Ramos-Jiménez J,
Barrera-Saldaña H, Rojas-Martínez A, Vidaltamayo R and
Rivas-Estilla AM: History and progress of antiviral drugs: From
acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C.
Medicina Universitaria. 17:165–174. 2015.
|
|
6
|
Harold C and Neu TDG: Antimicrobial
Chemotherapy, in Medical Microbiology. In: Medical Microbiology.
4th edition. Baron S, editor, University of Texas Medical Branch at
Galveston, 1996.
|
|
7
|
De Clercq E and Li G: Approved antiviral
drugs over the past 50 years. Clin Microbiol Rev. 29:695–747.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Clercq ED: Three decades of antiviral
drugs. Nat Rev Drug Discov. 6(941)2007.
|
|
9
|
Dal Pozzo F and Thiry E: Antiviral
chemotherapy in veterinary medicine: Current applications and
perspectives. Rev Sci Tech OIE. 33:791–801. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lewis W and Dalakas MC: Mitochondrial
toxicity of antiviral drugs. Nat Med. 1:417–422. 1995.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Morris DJ: Adverse effects and drug
interactions of clinical importance with antiviral drugs. Drug Saf.
10:281–291. 1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
De Clercq E: Fifty years in search of
selective antiviral drugs. J Med Chem. 62:7322–7339.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ryu WS: Life Virus Cycle. In: Molecular
Virology of Human Pathogenic Viruses. Elsevier, pp31-45, 2017.
|
|
14
|
Ghosn J, Taiwo B, Seedat S, Autran B and
Katlama C: HIV. Lancet. 392:685–697. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Vlachakis D, Tsiliki G, Pavlopoulou A,
Roubelakis MG, Tsaniras SC and Kossida S: Antiviral stratagems
against HIV-1 using RNA interference (RNAi) technology. Evol
Bioinform Online. 9:203–213. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lennox JL: Global HIV/AIDS Medicine. Emerg
Infect Dis. 14:1006–1007. 2008.
|
|
17
|
Menéndez-Arias L, Álvarez M and Pacheco B:
Nucleoside/nucleotide analog inhibitors of hepatitis B virus
polymerase: Mechanism of action and resistance. Curr Opin Virol.
8:1–9. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Anderson AC: Structure-Based Functional
Design of Drugs: From Target to Lead Compound. In: Molecular
Profiling. vol. 823 Espina V and Liotta LA (eds.) Humana Press,
Totowa, NJ, pp359-366, 2012.
|
|
19
|
Wouters OJ, McKee M and Luyten J:
Estimated research and development investment needed to bring a new
medicine to market, 2009-2018. JAMA. 323:844–853. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bajad NG, Rayala S, Gutti G, Sharma A,
Singh M, Kumar A and Singh SK: Systematic review on role of
structure based drug design (SBDD) in the identification of
anti-viral leads against SARS-Cov-2. Curr Res Pharmacol Drug
Discov. 2(100026)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vlachakis D, Papakonstantinou E, Mitsis T,
Pierouli K, Diakou I, Chrousos G and Bacopoulou F: Molecular
mechanisms of the novel coronavirus SARS-CoV-2 and potential
anti-COVID19 pharmacological targets since the outbreak of the
pandemic. Food Chem Toxicol. 146(111805)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang X, Song K, Li L and Chen L:
Structure-Based drug design strategies and challenges. Curr Top Med
Chem. 18:998–1006. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Martí-Renom MA, Stuart AC, Fiser A,
Sánchez R, Melo F and Šali A: Comparative protein structure
modeling of genes and genomes. Annu Rev Biophys Biomol Struct.
29:291–325. 2000.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Berman HM, Battistuz T, Bhat TN, Bluhm WF,
Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, et
al: The protein data bank. Acta Crystallogr D Biol Crystallogr.
58(Pt 6 No 1):899–907. 2002.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ekins S, Liebler J, Neves BJ, Lewis WG,
Coffee M, Bienstock R, Southan C and Andrade CH: Illustrating and
homology modeling the proteins of the Zika virus. F1000Res.
5(275)2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vlachakis D: Theoretical study of the
Usutu virus helicase 3D structure, by means of computer-aided
homology modelling. Theor Biol Med Model. 6(9)2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Illergård K, Ardell DH and Elofsson A:
Structure is three to ten times more conserved than sequence-a
study of structural response in protein cores. Proteins.
77:499–508. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vlachakis D and Kossida S: Molecular
modeling and pharmacophore elucidation study of the classical swine
fever virus helicase as a promising pharmacological target. PeerJ.
1(e85)2013.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Menéndez-Arias L and Gago F: Antiviral
agents: Structural basis of action and rational design. Subcell
Biochem. 68:599–630. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Anderson AC: The process of
structure-based drug design. Chem Biol. 10:787–797. 2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu J, Liu W and Gong P: A structural
overview of RNA-Dependent RNA polymerases from the flaviviridae
family. Int J Mol Sci. 16:12943–12957. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Papageorgiou L, Loukatou S, Sofia K,
Maroulis D and Vlachakis D: An updated evolutionary study of
Flaviviridae NS3 helicase and NS5 RNA-dependent RNA polymerase
reveals novel invariable motifs as potential pharmacological
targets. Mol Biosyst. 12:2080–2093. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abdel-Magid AF: Influenza RNA-Dependent
RNA Polymerase (RdRp) Inhibitors: Potential new therapy for
influenza treatment. ACS Med Chem Lett. 4:1133–1134.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen L, Morrow JK, Tran HT, Phatak SS,
Du-Cuny L and Zhang S: From laptop to benchtop to bedside:
Structure-based drug design on protein targets. Curr Pharm Des.
18:1217–1239. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yuriev E, Agostino M and Ramsland PA:
Challenges and advances in computational docking: 2009 in review. J
Mol Recognit. 24:149–164. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
Moitessier N, Englebienne P, Lee D,
Lawandi J and Corbeil CR: Towards the development of universal,
fast and highly accurate docking/scoring methods: A long way to go.
Br J Pharmacol. 153 (Suppl 1):S7–S26. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Davis IW and Baker D: RosettaLigand
docking with full ligand and receptor flexibility. J Mol Biol.
385:381–392. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fischer M, Coleman RG, Fraser JS and
Shoichet BK: Incorporation of protein flexibility and
conformational energy penalties in docking screens to improve
ligand discovery. Nat Chem. 6:575–583. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
De Vivo M, Masetti M, Bottegoni G and
Cavalli A: Role of molecular dynamics and related methods in drug
discovery. J Med Chem. 59:4035–4061. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang T, Wu MB, Zhang RH, Chen ZJ, Hua C,
Lin JP and Yang LR: Advances in computational structure-based drug
design and application in drug discovery. Curr Top Med Chem.
16:901–916. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Papageorgiou L, Loukatou S, Koumandou VL,
Makałowski W, Megalooikonomou V, Vlachakis D and Kossida S:
Structural models for the design of novel antiviral agents against
Greek Goat Encephalitis. PeerJ. 2(e664)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sacan A, Ekins S and Kortagere S:
Applications and limitations of in silico models in drug discovery.
Methods Mol Biol. 910:87–124. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ross GA, Morris GM and Biggin PC: One size
does not fit all: The limits of structure-based models in drug
discovery. J Chem Theory Comput. 9:4266–4274. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hess JF, Kohl TA, Kotrová M, Rönsch K,
Paprotka T, Mohr V, Hutzenlaub T, Brüggemann M, Zengerle R, Niemann
S and Paust N: Library preparation for next generation sequencing:
A review of automation strategies. Biotechnol Adv.
41(107537)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Luo H, Li M, Yang M, Wu FX, Li Y and Wang
J: Biomedical data and computational models for drug repositioning:
A comprehensive review. Brief Bioinform. 22:1604–1619.
2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Singh DB and Pathak RK: Bioinformatics:
Methods and applications. Academic Press, London, 2022.
|
|
47
|
Potok TE, Schuman C, Young S, Young S,
Patton R, Spedalieri F, Liu J, Yao KT, Rose G and Chakma G: A study
of complex deep learning networks on high-performance,
neuromorphic, and quantum computers. J Emerg Technol Comput Syst.
14:1–21. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sharma P and Singh A: Era of deep neural
networks: A review. In: 2017 8th International Conference on
Computing, Communication and Networking Technologies (ICCCNT).
IEEE, Delhi, pp1-5, 2017.
|
|
49
|
Mahendran ASK, Lim YS, Fang CM, Loh HS and
Le CF: The potential of antiviral peptides as COVID-19
therapeutics. Front Pharmacol. 11(575444)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Timmons PB and Hewage CM: ENNAVIA is a
novel method which employs neural networks for antiviral and
anti-coronavirus activity prediction for therapeutic peptides.
Brief Bioinform. 22(bbab258)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Santana K, do Nascimento LD, Lima E, Lima
A, Damasceno V, Nahum C, Braga RC and Lameira J: Applications of
virtual screening in bioprospecting: Facts, shifts, and
perspectives to explore the chemo-structural diversity of natural
products. Front Chem. 9(662688)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Joshi T, Joshi T, Sharma P, Mathpal S,
Pundir H, Bhatt V and Chandra S: In silico screening of natural
compounds against COVID-19 by targeting Mpro and ACE2 using
molecular docking. Eur Rev Med Pharmacol Sci. 24:4529–4536.
2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Alzubaidi L, Zhang J, Humaidi AJ,
Al-Dujaili A, Duan Y, Al-Shamma O, Santamaría J, Fadhel MA,
Al-Amidie M and Farhan L: Review of deep learning: Concepts, CNN
architectures, challenges, applications, future directions. J Big
Data. 8(53)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cao C, Liu F, Tan H, Song D, Shu W, Li W,
Zhou Y, Bo X and Xie Z: Deep learning and its applications in
biomedicine. Genomics Proteomics Bioinformatics. 16:17–32.
2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Skolnick J, Gao M, Zhou H and Singh S:
AlphaFold 2: Why it works and its implications for understanding
the relationships of protein sequence, structure, and function. J
Chem Inf Model. 61:4827–4831. 2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Varadi M, Anyango S, Deshpande M, Nair S,
Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al:
AlphaFold protein structure database: Massively expanding the
structural coverage of protein-sequence space with high-accuracy
models. Nucleic Acids Res. 50(D1):D439–D444. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Mirdita M, Schütze K, Moriwaki Y, Heo L,
Ovchinnikov S and Steinegger M: ColabFold: Making protein folding
accessible to all. Nat Methods. 19:679–682. 2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Robertson AJ, Courtney JM, Shen Y, Ying J
and Bax A: Concordance of X-ray and AlphaFold2 Models of SARS-CoV-2
main protease with residual dipolar couplings measured in solution.
J Am Chem Soc. 143:19306–19310. 2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang D, Cui C, Ding X, Xiong Z, Zheng M,
Luo X, Jiang H and Chen K: Improving the virtual screening ability
of target-specific scoring functions using deep learning methods.
Front Pharmacol. 10(924)2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhang Y, Ye T, Xi H, Juhas M and Li J:
Deep learning driven drug discovery: Tackling severe acute
respiratory syndrome coronavirus 2. Front Microbiol.
12(739684)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Gawriljuk VO, Foil DH, Puhl AC, Zorn KM,
Lane TR, Riabova O, Makarov V, Godoy AS, Oliva G and Ekins S:
Development of machine learning models and the discovery of a new
antiviral compound against yellow fever virus. J Chem Inf Model.
61:3804–3813. 2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Anantpadma M, Lane T, Zorn KM, Lingerfelt
MA, Clark AM, Freundlich JS, Davey RA, Madrid PB and Ekins S: Ebola
virus bayesian machine learning models enable new in vitro leads.
ACS Omega. 4:2353–2361. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Francoeur PG, Masuda T, Sunseri J, Jia A,
Iovanisci RB, Snyder I and Koes DR: Three-Dimensional convolutional
neural networks and a cross-docked data set for structure-based
drug design. J Chem Inf Model. 60:4200–4215. 2020.PubMed/NCBI View Article : Google Scholar
|
